SPRC — SciSparc Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1611746 ·
Last close
$6.66
Market Cap
$3.82M
52W High
$15.79
52W Low
$4.23
ADV30
353,681
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 7,622,000 | 4,591,000 | 2,475,000 |
| Jun 2025 | — | — | — | — | 5,139,000 | 1,545,000 | 5,220,000 |
| Dec 2024 | — | — | — | — | 10,347,000 | 1,540,000 | 1,408,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-87,154,000
Inventory
$75,000
Receivables
$662,000
ST Investments
$0
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$856,000
EBITDA
$-8,528,000
Free Cash Flow
$833,000
Enterprise Value
$520,861
Total Cash
$4,591,000
Total Debt
$366,000
Shares Out
573,243
Trailing EPS
$98.07
Book Value
$11.60
ROE
-178.4%
ROA
-60.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 856,000 | -8,749,000 | -12,179,000 | 7,622,000 | 2,475,000 | — | -4,137,000 |
| Dec 2024 | 1,306,000 | -7,242,000 | -6,284,000 | 10,347,000 | 1,408,000 | — | -5,104,000 |
| Dec 2023 | 2,879,000 | -5,773,000 | -5,122,000 | 11,182,000 | 1,595,000 | — | -5,887,000 |
| Dec 2022 | 1,347,000 | -8,287,000 | -2,592,000 | 10,605,000 | 4,156,000 | — | -7,917,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $3.80M | $1.08 | — |
| GRI | GRI Bio, Inc. | $3.91M | $1.79 | — |
| MBIO | MUSTANG BIO, INC. | $3.71M | $0.55 | — |
| RDHL | RedHill Biopharma Ltd. | $3.68M | $0.61 | — |
| ISCO | International Stem Cell CORP | $3.99M | $0.50 | — |
News headlines (Yahoo Finance, 1h cache)
SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
2026-08-24 12:51 · Yahoo
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
2026-08-18 12:06 · Yahoo
SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination
2026-08-12 12:25 · Yahoo
SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
2026-08-05 12:22 · Yahoo
SciSparc: Subsidiary NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics
2026-07-31 12:20 · Yahoo
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
2026-07-29 12:32 · Yahoo
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement
2026-08-12 21:01 · Yahoo
NeuroThera Labs Granted Japanese Patent for Its Proprietary, Innovative Therapeutic Combination
2026-08-12 13:00 · Yahoo
SciSparc Advances Quantum Clinical Data Analytics as NeuroThera Validates Proprietary Computing Platform
2026-07-29 14:30 · Yahoo
SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity
2026-07-27 12:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.